Morphine

Limits on what this shows

• Null findings: No human mitochondrial measurement was found.
• At-risk subgroups: Not defined.

Regulatory status

Not mentioned in the retrieved label text [1].

Population evidence

Dorsch 2016 [15]: male Wistar rats (n = 6 per group in vivo; n = 7 for cardiomyocytes). Morphine 0.3 mg/kg IV reduced infarct size from 64% to 39% (P < 0.05); the mPTP opener atractyloside abolished this (65%), and cyclosporine A partly restored protection (31%); morphine increased phospholamban phosphorylation at 10 uM, indicating PKA activation. Mitochondrial ROS, membrane potential and calcium were not measured. Full text read via a summarizing fetch tool. Skrabalova 2013 [14] reviews morphine-induced oxidative damage in several tissues. Kashiwagi 2021 [16] (rat spinal morphine tolerance, mitochondrial superoxide, PGC-1 alpha) was identified by title and metadata only; its abstract was not obtained and it is not used for grading. Tier B, morphine-specific, rodent.

Mechanism

Named in rats: opening of the mitochondrial permeability transition pore is part of the acute cardioprotective pathway [15]. Chronic mitochondrial effects are suggested but not read.

Direction

Mixed: acute protective in one rat model [15], damage-associated in the reviewed chronic literature [14]. Neither maps to a nutrient.

Counter-evidence held on record

Counter-evidence The only mitochondrial paper actually read [15] shows a protective acute effect, which argues against a simple "mitochondrial toxicity" claim. Framing caution Theoretical. Do not state that morphine damages mitochondria or lowers energy in patients. No supplement (such as coenzyme Q10) is recommended from this entry.

Limits on what this shows

• Null findings: None located. Absence of a human study means no null or positive human result exists in what I opened.
• At-risk subgroups: Not defined.

Regulatory status

Not mentioned in the retrieved label text [1].

Population evidence

Zhang 2004 [13]: mouse liver after morphine administration showed higher 8-OHdG, protein carbonyls and malondialdehyde with lower antioxidant enzyme activity; co-administered glutathione and ascorbic acid abolished the damage (abstract excerpt via Crossref). Skrabalova 2013 [14]: narrative review stating chronic morphine exposure produces oxidative stress and apoptosis, with different tissues (brain, liver, cardiovascular system, macrophages) responding differently (abstract only, via OpenAlex). Tier B (animal, morphine-specific) plus a narrative review.

Mechanism

Present in animals: reactive oxygen and nitrogen species generation. Doses and exposure in the animal work were not captured and are not assumed to match human therapy.

Direction

Excess oxidative burden in animal tissue. This is not evidence of vitamin C or glutathione depletion in patients: the antioxidant arms in [13] were pharmacologic protection experiments in mice.

Counter-evidence held on record

Counter-evidence Acute morphine appeared protective in an ischemia-reperfusion model (see Mitochondrial burden) [15], so the direction depends on tissue, dose and time. Framing caution Theoretical and animal only. Do not present as an expected effect in patients and do not recommend antioxidant supplements. No dose is recommended.

Limits on what this shows

• Null findings: None located. No human study and no hepatic copper or ceruloplasmin result could be read.
• At-risk subgroups: Not defined.

Regulatory status

No copper content in the retrieved label text [1].

Population evidence

Yousofvand 2014 [23]: 24 adult male Wistar rats in two groups; morphine given subcutaneously twice daily for 30 days, starting at 10 mg/kg and rising 2 mg/kg per day to a maximum of 68 mg/kg, versus saline controls; serum copper, zinc and manganese measured by inductively coupled plasma optical emission spectrometry. Serum copper and zinc were significantly higher (p < 0.05) and manganese significantly lower in morphine-dependent rats (Student t test; group means were not shown in the page I opened). Iwata and Watanabe 1971 [18]: the J-STAGE abstract was opened; it states that earlier work found plasma copper increased in morphine-tolerant animals and that this paper examined serum copper, ceruloplasmin, hepatic copper and biliary copper excretion in morphine-tolerant rats, but the abstract text does not give this paper's own results. The companion papers [19][20] were opened only as OpenAlex metadata (abstracts null). Tier B (animal, morphine-specific).

Mechanism

None named in the sources opened. The 1971 abstract frames copper in relation to morphine analgesia and tolerance [18], not nutrient handling.

Direction

Serum copper higher (excess or redistribution direction in animal serum), not depletion. The same rat study reported higher zinc and lower manganese [23]; those are not graded here and are flagged for the next revision.

Counter-evidence held on record

Counter-evidence and confounding One small rat study (12 per group) of high escalating doses with withdrawal testing in some animals; stress or inflammatory responses could raise serum copper independent of any nutrient effect (a reasoning note, not a finding of the paper). It is a serum value and does not show tissue copper status. Doses up to 68 mg/kg in rats are not a human oral dosing equivalent. Framing caution Animal serum finding in the excess direction. It is not evidence that patients are copper deficient or copper overloaded, and neither copper supplementation nor copper restriction follows from it. No supplement dose is recommended.

Limits on what this shows

• Null findings: None located, and none sought in the sense of a measured null: no study of systemic iron indices in morphine users or treated animals was opened, so absence of a systemic effect is not shown.
• At-risk subgroups: Not defined.

Regulatory status

No iron content in the retrieved label text [1].

Population evidence

Nash 2019 [24]: rat cortical neurons in culture plus morphine-treated rats. Morphine dose-dependently raised ferritin heavy chain through the mu-opioid receptor and G-alpha-i signaling, also raised ferritin light chain, and increased cytoplasmic labile iron while endolysosomal iron fell; iron chelation blocked morphine-induced dendritic spine loss and endolysosomal iron overloading mimicked it; morphine-treated rats had more ferritin heavy chain in prefrontal cortex layer 2/3 neurons (abstract read via OpenAlex, with an exposure of 24 hours in culture per a Society for Neuroscience summary; the full text was blocked and in vivo dosing was not captured). Vakili 2023 [26]: 16 female Wistar rats (8 per group), morphine sulfate 5 mg/kg intraperitoneally once daily for 2 days versus saline; potassium ferricyanide staining showed significantly more iron deposits in ovarian tissue and EGF receptor density was higher; serum iron, ferritin, hemoglobin and transferrin were not measured. Nash 2021 [25] is a book chapter by the same lab reviewing the neuronal work and is not an independent confirmation. Tier B, morphine-specific, rodent.

Mechanism

Named in neurons: mu-opioid receptor signaling that releases endolysosomal iron into the cytoplasm and induces ferritin [24]. The ovarian mechanism (nitric oxide, hyperemia, EGF) is proposed by the authors and not established [26].

Direction

Redistribution and local accumulation (excess direction in cells and tissue), not iron deficiency. It does not indicate low systemic iron or a need for more iron intake.

Counter-evidence held on record

Counter-evidence and confounding Cell culture and a two-day rat injection model at 5 mg/kg; the ovarian result is histology only, and local hyperemia or bleeding could deposit iron (a reasoning note, not a finding of the paper). The authors call the ovarian finding "hemochromatosis", which here means local deposits, not systemic iron overload. Anemia in patients, if present, is an outcome and not an iron finding (Hard Rule 2). Framing caution Cellular and animal tissue findings only. Do not read this as iron deficiency or iron overload in patients, and do not imply iron supplements or iron restriction. No supplement dose is recommended.

Limits on what this shows

• Null findings: Wang 2018 [5] did not report vitamins, SCFAs, B vitamins, folate or vitamin D, so no nutrient-level microbial output (such as microbial B vitamin synthesis) was shown to change. No human morphine microbiome null result was found.
• At-risk subgroups: Not defined from these sources. The mouse regimen (continuous 1 uM exposure) is not a human oral dosing equivalent.

Regulatory status

Not mentioned in the retrieved label text [1]. The label does document the underlying gut dysmotility (reduced propulsion, constipation, reduced biliary and pancreatic secretion) [1].

Population evidence

Banerjee 2016 [4]: C57BL/6 mice with 25 mg slow-release morphine pellets (about 1 uM serum), analyzed at 72 hours, n = 6 per group. As summarized: Firmicutes up, Bacteroidetes down, expansion of Enterococcaceae, Staphylococcaceae and Streptococcaceae, fewer Lactobacillus and Clostridium, lower primary and secondary fecal bile acids, bacterial translocation to liver, higher IL-17 and IL-6; naltrexone co-implantation prevented the dysbiosis and microbiota transplant rescued it. Wang 2018 [5]: pellet model, alpha diversity (chao1) down by day 3 (P = 0.003), Enterococcus faecalis expanded about 100-fold, Bacteroidales down, bile acids down, and a higher M3G to morphine ratio consistent with reduced bacterial deconjugation. Kang 2017 [6]: antibiotic gut depletion prevented morphine-induced gut permeability, colonic mucosal destruction, colonic IL-1 beta rise and antinociceptive tolerance (abstract excerpt only). Tier B, morphine-specific, mouse.

Mechanism

Named in mice: opioid-receptor mediated (naltrexone prevents) loss of bile acid signaling and barrier function with bacterial translocation [4][5]. Slowed transit from the drug (constipation, a drug effect, not a nutrient) is a plausible human contributor and is not separated from the microbial effect in these sources.

Class extrapolation

CLASS EXTRAPOLATION, human data. Cruz-Lebron 2021 [7] studied people on methadone maintenance: dysbiosis with imbalance in short-chain-fatty-acid producers and mucin degraders, reduced fecal SCFAs, and barrier effects via Akkermansia metabolites in vitro. Morphine was NOT in that cohort (abstract read via OpenAlex). Cohort test: the shared element is mu-opioid receptor agonism with gut dysmotility, which the morphine mouse work supports [4], but methadone differs in pharmacology, so this is capped at yellow.

Counter-evidence held on record

Counter-evidence and confounding Small mouse groups (n = 4 to 8), a pellet model that differs from oral human dosing, and human data from a different opioid. In people, diet, constipation, co-medications and bowel regimens confound microbiome findings. I read Banerjee and Wang through a summarizing fetch tool, not independently. Framing caution A monitoring prompt about bowel function, not a finding that morphine causes a nutrient deficiency. No probiotic, fiber or other supplement is recommended from this entry.

Limits on what this shows

• Null findings: None located; no hematologic measurement was found.
• At-risk subgroups: Per label: concurrent CNS depressants, renal or hepatic impairment, and P-gp inhibitors that raise exposure [1].

Regulatory status

Label sec 12.2: morphine produces respiratory depression by direct brainstem action, reducing responsiveness to rising CO2; hypoxia may occur in overdose [1]. Sedation and respiratory depression risk rises with CNS depressants [1].

Population evidence

No red-cell mass, hemoglobin, hematocrit or tissue-oxygen study in morphine users was opened. Tier A label only, for respiratory depression.

Mechanism

Named: central respiratory depression. Intended and adverse pharmacology, not depletion (Hard Rule 2).

Counter-evidence held on record

Counter-evidence Any hemoglobin effect through hypogonadism or nutrient absorption would belong to the androgen or iron entries and is not counted twice (see Overlap map). Framing caution Not a nutrient entry. Do not imply iron, B12 or oxygen-support supplements from respiratory depression.

Limits on what this shows

• Null findings: Most respiratory and membrane potential parameters were unchanged by morphine alone [28][29]; the 1975 work found ATP synthetase itself unaffected [27].
• At-risk subgroups: Not defined.

Regulatory status

Not mentioned in the retrieved label text [1].

Population evidence

Gegenava and Chistyakov 1975 [27]: isolated rat liver mitochondria; morphine inhibited substrate oxidation in the presence of ADP, lowered the phosphorylation rate and lowered dinitrophenol-stimulated ATPase activity, all with an inhibition constant of 6.5 mM; uncoupled respiration and ATP synthetase and ATPase of submitochondrial particles were not inhibited; the authors postulate inhibition of adenine nucleotide transfer across the mitochondrial membrane (abstract only). Cunha-Oliveira 2013, Life Sciences [29]: isolated rat liver mitochondria at 0.2, 0.4 and 1 mM morphine; morphine alone only increased resting-state respiration, did not affect most respiratory parameters, had no effect on membrane potential or ADP-induced depolarization, and at 1 mM significantly decreased ATPase activity. Cunha-Oliveira 2013, Toxicology Letters [28]: isolated rat brain and liver mitochondria at 1 mM; the abstract states morphine "presented only slight effects"; with complex I substrates brain respiratory control ratio fell about 15% (p < 0.01) with no significant change in state 2, 3 or 4 respiration; in liver with complex II substrates state 2 rose about 18%, state 4 about 16% and respiratory control ratio fell about 33%. Cocaine and cocaine plus morphine arms in [28][29] are not counted for morphine. ATP content itself was not measured in any of these. Tier B, morphine-specific, in vitro rat.

Mechanism

Proposed in [27]: inhibition of adenine nucleotide translocation. Not shown in intact cells, animals or people.

Direction

Mixed and small: some inhibition of phosphorylation and ATPase, some increased resting respiration. It does not describe an energy deficit in patients.

Counter-evidence held on record

Counter-evidence and confounding Concentrations were 0.2 to 6.5 mM, whereas the authors of [29] cite peak plasma morphine of 0.35 to 9.8 uM, a gap of roughly 20 to 20,000 fold. Isolated organelles lack the cellular context in which intracellular drug accumulation or compensation would occur. [29] also reported that morphine reduced hydrogen peroxide formation and lipid peroxidation under induced oxidative stress, which runs against the Oxidative stress entry above (see Overlap map). Framing caution In vitro only. Do not state that morphine lowers cellular energy or causes fatigue through mitochondrial effects, and do not recommend coenzyme Q10 or similar products. No supplement dose is recommended.